Prosecution Insights
Last updated: April 19, 2026
Application No. 18/366,299

SENSORS FOR 3-HYDROXYBUTYRATE DETECTION

Non-Final OA §103
Filed
Aug 07, 2023
Examiner
ROZANSKI, GRACE NMN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Medtronic Minimed, Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Moderate
1-2
OA Rounds
4y 1m
To Grant
70%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
48 granted / 74 resolved
-5.1% vs TC avg
Minimal +5% lift
Without
With
+4.6%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
44 currently pending
Career history
118
Total Applications
across all art units

Statute-Specific Performance

§101
15.9%
-24.1% vs TC avg
§103
55.4%
+15.4% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
14.9%
-25.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 74 resolved cases

Office Action

§103
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statements (IDS) submitted on 08/12/24, 06/20/24 and 05/09/24 have been considered by the examiner. Election/Restrictions Applicant's election with traverse of Invention I (Claims 1-9 and 21) in the reply filed on 02/09/26 is acknowledged. The traversal is on the ground(s) that Applicant notes the subject matter of each of the claim Groups is linked by a common inventive concept, and there is no serious burden on the Examiner to examine the different claim Groups. This is not found persuasive because the process of Invention II can be used to practice another and materially different apparatus than Invention I that comprises an electrical conduit. Additionally, the apparatus of Invention I can be used to practice another and materially different process than Invention III, that comprises external skin sensing. Invention II (Claims 10-19) and Invention III (Claim 20) have been withdrawn The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6, 8, 9 and 21 are rejected under 35 U.S.C. 103 as being anticipated by Feldman (U.S. Patent Application Publication 2020/0237275 A1) and in further view of Ouyang (U.S. Patent Application Publication 2019/0024130 A1) Feldman was applied in the Applicant’s IDS filed on 08/12/24 Regarding claim 1, Feldman teaches an amperometric analyte sensor system [fig. 3A, element 200; par. 44] comprising: a 3-hydroxybutyrate sensing electrode [fig. 3A, element 214; par. 12, 24] comprising: a layer of an electroactive material [fig. 3A, element 218b; par. 44, 45, 75, Examiner notes the active area comprises conductive material]; an enzyme layer comprising 3-hydroxybutyrate dehydrogenase enzyme in operable contact with the electroactive material [par. 32, 36]; a nicotinamide adenine dinucleotide in operable contact with the 3-hydroxybutyrate dehydrogenase enzyme [par. 36, 70]; a mediator in operable contact with the nicotinamide adenine dinucleotide [par. 36 “The NADH may then undergo reduction under diaphorase mediation, with the electrons transferred during this process providing the basis for ketone detection at the working electrode”, par. 70]; and a ketone modulating layer disposed over the enzyme layer [fig. 3A, element 220; par. 32, 45], wherein the ketone modulating layer comprises a composition that modulates the diffusion of ketones through the ketone modulating layer [par. 70] However, Feldman does not teach the 3-hydroxybutyrate modulating layer comprises a composition that modulates the diffusion of 3-hydroxybutyrate through the 3-hydroxybutyrate modulating layer Ouyang teaches 3-hydroxybutyrate modulating layer comprises a composition that modulates the diffusion of 3-hydroxybutyrate through the 3-hydroxybutyrate modulating layer [par. 50] Therefore, it would have been prima facie obvious to person having ordinary skill in the art when the invention was filed to modify Feldman to incorporate c3-hydroxybutyrate modulating layer comprises a composition that modulates the diffusion of 3-hydroxybutyrate through the 3-hydroxybutyrate modulating layer, to reduce the rate of mass transport of the analyte, as evidence by Ouyang [par. 50] Regarding claim 2, Feldman further teaches the 3-hydroxybutyrate dehydrogenase enzyme, the mediator and/or the nicotinamide adenine dinucleotide is tethered/coupled to a polymer [par. 36]. Regarding claim 3, Feldman further teaches the polymer comprises a polyvinyl pyridine [par. 64, 65] Regarding claim 4, Feldman further teaches the 3-hydroxybutyrate dehydrogenase enzyme, the mediator and/or the nicotinamide adenine dinucleotide is tethered/coupled to a polymer via crosslinking agent [par. 65, 67] Regarding claim 5, Feldman further teaches the polymer is operably coupled to the 3-hydroxybutyrate sensing electrode [par. 65, 136] Regarding claim 6, Feldman further teaches the mediator comprises: an organo-metallic phenanthroline-dione, and/or Meldola blue [par. 39] Regarding claim 8, Feldman further teaches the amperometric analyte sensor system does not comprise a diaphorase [par. 38 “β-hydroxybutyrate dehydrogenase (HBDH) may again convert β-hydroxybutyrate and NAD into acetoacetate and NADH, respectively. Instead of electron transfer to the working electrode being completed by diaphorase (see FIG. 2A) and a transition metal electron transfer agent, the reduced form of NADH oxidase (NADHOx (Red)) undergoes a reaction to form the corresponding oxidized form (NADHOx (Ox))”] Regarding claim 9, Feldman further teaches the amperometric analyte sensor system senses 3-hydroxybutyrate at an electrical potential of less than 0.7V, 0.6V, 0.5V, 0.4V, 0.3V, or 0.2V [par. 73]. Regarding claim 21, Feldman further teaches a glucose sensing electrode [fig. 3A, element 214; par. 44] comprising: a layer of an electroactive material [fig. 3A, element 218b; par. 44, 45, 75, Examiner notes the active area comprises conductive material]; an enzyme layer comprising glucose oxidase enzyme in operable contact with the electroactive material [par. 40]; and a glucose modulating layer disposed over the enzyme layer [fig. 3A, element 220; par. 27, 45], wherein: the glucose modulating layer comprises a composition that modulates the diffusion of glucose through the glucose modulating layer [par. 27]; and the amperometric analyte sensor system senses 3-hydroxybutyrate and glucose [par. 12, 24, 45] Claim 7 is rejected under 35 U.S.C. 103 as being anticipated by Feldman and Ouyang and in further view of Liang (U.S. Patent Application Publication 2022/0304599 A1) Regarding claim 7, Feldman and Ouyang teach an amperometric analyte sensor system, as disclosed above. However, Feldman and Ouyang do not teach the mediator: is embedded within a screen printed carbon electrode; and/or is coupled to the electrode via an electropolymerization process Liang teaches the mediator: is embedded within a screen printed carbon electrode; and/or is coupled to the electrode via an electropolymerization process Therefore, it would have been prima facie obvious to person having ordinary skill in the art when the invention was filed to modify Feldman and Ouyang, to incorporate the mediator: is embedded within a screen printed carbon electrode; and/or is coupled to the electrode via an electropolymerization process, to dictate conductance of the resulting mediator-enzyme-cofactor matrix, as evidence by Liang [par. 37] Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to GRACE L ROZANSKI whose telephone number is (571)272-7067. The examiner can normally be reached M-F 8:30am-5pm, alt F 8:30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached on (571)272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GRACE L ROZANSKI/ Examiner, Art Unit 3791 /ALEX M VALVIS/Supervisory Patent Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Aug 07, 2023
Application Filed
Mar 13, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599318
IMPLANTABLE MICRO-BIOSENSOR AND METHOD FOR OPERATING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594010
MINIMALLY INVASIVE SKIN PATCH, METHOD OF MANUFACTURING SAME, AND BLOOD GLUCOSE MEASURING APPARATUS USING SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12588843
SENSOR WITH SUBSTRATE INCLUDING INTEGRATED ELECTRICAL AND CHEMICAL COMPONENTS AND METHODS FOR FABRICATING THE SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12575797
BLOOD GLUCOSE DISEASE MANAGEMENT SYSTEM
2y 5m to grant Granted Mar 17, 2026
Patent 12533056
PHYSIOLOGICAL SIGNAL MONITORING DEVICE WITH AN ELECTROSTATIC-DISCHARGE PROTECTIVE MECHANISM
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
70%
With Interview (+4.6%)
4y 1m
Median Time to Grant
Low
PTA Risk
Based on 74 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month